VitaDisc® for intervertebral disc degeneration
VitaDisc® is a non-cellular and non-opioid biologic therapy that targets Chronic Lower Back Pain (CLBP) due to Intervertebral Disc Degeneration (IVDD). IVDD is the most common cause of CLBP, associated with ~40% of cases. It is a slowly progressive condition that evolves over decades in a self-amplifying disease cycle. This means it lends itself very well to early, disease-modifying intervention.
VitaDisc® tackles the disease before irreversible damage (such as annular tears or disc herniation) occurs and resets the state of the disc to its healthy baseline. When administered to discs with Pfirrmann grades II-IV degeneration, VitaDisc®’s effects are expected to last years. VitaDisc® can be easily repeated with no cumulative morbidity.
VitaDisc® comes as a powder to optimise shelf life. When a patient requires therapy, the powder is mixed with a saline solution to form a viscous gel. The physician then injects this gel into the affected disc through a very thin needle. The intervention will have minimal recovery time (<1 day) and will integrate seamlessly into the workflow of the interventional pain physician or spinal surgeon, in the ambulatory setting, requiring no additional training or equipment.
Read more about the science behind our technology
Osteoarthritis products for synovial joints
We are currently at the R&D stage, exploring the technology’s potential as a stand-alone bioactive material and as an inducer to pluripotent stem cells.
We have thus far seen evidence in bovine and human cell cultures that the solubilized notochordal matrix powder is capable of stimulating native or pluripotent stem cells to proliferate and produce a substantial increase in glycosaminoglycans and type-II collagen matrix, as well as create cartilage organoids.